EX-99.1 2 estaprq12025-ex991.htm EX-99.1 Document EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 rdenhoy@establishmentlabs.com Establishment Labs Reports First Quarter 2025 Financial Results NEW YORK, NY, May 7, 2025 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2025. First Quarter Highlights and Outlook (Unaudited) • First quarter worldwide revenue of $41.4 million, including $6.2 million of Motiva sales in the United States. • 2025 revenue guidance maintained at $205 million to $210 million, year over year growth of 23% - 26%. • First quarter gross margin of 67.2% compared to 65.6% in the year-ago period. • First quarter loss from operations was $16.9 million compared to a loss of $8.8 million in the year-ago period. • First quarter adjusted EBITDA loss of $12.1 million compared to a loss of $4.0 million in the year-ago period. • First quarter cash use…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Establishment Labs Holdings Inc.
ESTANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 7, 2025, Establishment Labs Holdings Inc. (the “Company”) issued a press release announcing the Company’s financial results for the three months ended March 31, 2025 and recent corporate highlights.…
Company context
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zen™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 2